- £863.00m
- £1.11bn
- £787.60m
- 82
- 51
- 100
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.92 | ||
| PEG Ratio (f) | 1.04 | ||
| EPS Growth (f) | 20.74% | ||
| Dividend Yield (f) | 2.75% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.36 | ||
| Price to Tang. Book | 9.34 | ||
| Price to Free Cashflow | 4.86 | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | 9.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.06% | ||
| Return on Equity | 1.23% | ||
| Operating Margin | 4.7% | ||
Financial Summary
| Year End 30th Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 773 | 908.3 | 1,000.3 | 877.1 | 787.6 | 807.87 | 849.17 | 3.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -8.76 | +135.59 | -27.06 | -46.77 | -44.14 | +9.43 | +29.08 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dr. Martens plc is a United Kingdom-based company, which designs, develops, procures, markets, sells and distributes footwear, under the Dr. Martens brand. The Company’s segments include Europe, the Middle East and Africa (EMEA); Americas; and Americas and Asia-Pacific (APAC). Its product segments include boots, shoes, sandals, and bags & other. Its boots offerings include the 1460 8-eye boot, 2976 Chelsea boot, Jadon, Bex and Sinclair. Its shoes offerings include 1461 3-eye shoe and the Adrian tassel loafer, as well as franchises/families such as Buzz and Lowell. Its sandals range includes Blaire and Gryphon silhouettes and also includes the mules range, led by the Zebzag. Its bag range is focused on key silhouettes of leather bags, such as the Kiev backpack, the heart-shaped bag and its weekender bag. This category also includes socks, laces and shoe care. The Company offers its products through direct-to-consumer channel via its ecommerce platforms and its stores, among others.
Directors
- Paul Mason NEC (60)
- Kenny Wilson CEO (54)
- Jon Mortimore CFO (53)
- Emily Reichwald GCN (45)
- Tara Alhadeff NED (39)
- Ije Nwokorie NID (50)
- Robyn Perriss NID (47)
- Ian Rogers NID (47)
- Lynne Weedall NID
- Last Annual
- March 30th, 2025
- Last Interim
- March 30th, 2025
- Incorporated
- October 19th, 2020
- Public Since
- January 29th, 2021
- No. of Employees
- 2,348
- Sector
- Textiles & Apparel
- Industry
- Consumer Cyclicals
- Exchange
London Stock Exchange- Shares in Issue
- 966,407,209
- Address
- 28 Jamestown Rd, Camden, LONDON, NW1 7BY
- Web
- https://www.drmartensplc.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Latest News for DOCS
Upcoming Events for DOCS
Half Year 2026 Dr Martens PLC Earnings Release
Similar to DOCS
Coats
London Stock Exchange
Johnson Service
London Stock Exchange
Mothercare
London Stock Exchange
Mulberry
London Stock Exchange
FAQ
As of Today at 20:20 UTC, shares in Dr Martens are trading at 89.30p. This share price information is delayed by 15 minutes.
Shares in Dr Martens last closed at 89.30p and the price had moved by +63.55% over the past 365 days. In terms of relative price strength the Dr Martens share price has outperformed the FTSE All Share Index by +47.81% over the past year.
The overall consensus recommendation for Dr Martens is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Dr Martens dividend yield is 2.86% based on the trailing twelve month period.
Last year, Dr Martens paid a total dividend of £0.03, and it currently has a trailing dividend yield of 2.86%. We do not have any data on when Dr Martens is to next pay dividends.
We do not have data on when Dr Martens is to next pay dividends. The historic dividend yield on Dr Martens shares is currently 2.86%.
To buy shares in Dr Martens you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 89.30p, shares in Dr Martens had a market capitalisation of £863.00m.
Here are the trading details for Dr Martens:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: DOCS
Based on an overall assessment of its quality, value and momentum Dr Martens is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dr Martens is 106.17p. That is 18.89% above the last closing price of 89.30p.
Analysts covering Dr Martens currently have a consensus Earnings Per Share (EPS) forecast of £0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dr Martens. Over the past six months, its share price has outperformed the FTSE All Share Index by +50.38%.
As of the last closing price of 89.30p, shares in Dr Martens were trading +24.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dr Martens PE ratio based on its reported earnings over the past 12 months is 17.92. The shares last closed at 89.30p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dr Martens' management team is headed by:
- Paul Mason - NEC
- Kenny Wilson - CEO
- Jon Mortimore - CFO
- Emily Reichwald - GCN
- Tara Alhadeff - NED
- Ije Nwokorie - NID
- Robyn Perriss - NID
- Ian Rogers - NID
- Lynne Weedall - NID